Ken Griffin Adma Biologics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$11.21 - $20.03 $995,448 - $1.78 Million	88,800 Added 73.15%	210,200 $4.2 Million
Q2 2024 Aug 14, 2024	BUY	$5.98 - $11.18 $583,648 - $1.09 Million	97,600 Added 410.08%	121,400 $1.36 Million
Q1 2024 May 15, 2024	BUY	$4.4 - $6.74 $99,000 - $151,650	22,500 Added 1730.77%	23,800 $157,000
Q4 2023 Feb 14, 2024	SELL	$3.08 - $4.52 $11,088 - $16,271	-3,600 Reduced 73.47%	1,300 $5,000
Q3 2023 Nov 14, 2023	SELL	$3.47 - $4.61 $23,249 - $30,887	-6,700 Reduced 57.76%	4,900 $17,000
Q2 2023 Aug 14, 2023	SELL	$3.12 - $4.22 $9,048 - $12,238	-2,900 Reduced 20.0%	11,600 $42,000
Q1 2023 May 15, 2023	SELL	$3.01 - $3.87 $498,154 - $640,485	-165,500 Reduced 91.94%	14,500 $47,000
Q4 2022 Feb 14, 2023	BUY	$2.47 - $3.88 $143,013 - $224,652	57,900 Added 47.42%	180,000 $698,000
Q3 2022 Nov 14, 2022	SELL	$2.03 - $2.86 $39,381 - $55,484	-19,400 Reduced 13.71%	122,100 $297,000

319

184M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.51B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.